ASLAN Pharmaceuticals Limited (NASDAQ:ASLN) traded at $2.05 at last check on Friday, Oct 16, making an upward move of 7.33% on its previous day’s price.
Looking at the stock we see that its previous close was $1.91 and the beta (5Y monthly) reads 0 with the day’s price range being $1.9600 – 2.4600. The company has a 12-month trailing PE ratio of 0. In terms of its 52-week price range, ASLN has a high of $8.18 and a low of $0.35. The company’s stock has gained about 34.87% over that past 30 days.
ASLAN has a market cap of $77.88 Million and is expected to release its quarterly earnings report in Aug. With its Forward Dividend at 0 and a yield of 0%, the company’s investors could be worried for the ASLN stock to lose ahead of the earnings release. Estimates by analysts give the company expected earnings per share (EPS) of -$0.09, with the EPS growth for the year raised at -$0.4 for 2020 and -$0.7 for next year. These figures represent -0.72% and at 0.75% growth in EPS for the two years respectively.
On the other hand, looking at the outlook for the ASLN stock, short term indicators assign the stock an average of 100% Buy, while medium term indicators assign it an average of Hold. Long term indicators on average place the stock in the category of 75% Buy.
Based on estimates by 3 analysts where scores have ranged from 1.00 for a strong buy to 5.00 for a strong sell, 1 have rated the ASLAN Pharmaceuticals Limited (ASLN) stock as a Hold, while 2 rate it as a Buy. None analysts rate it as outperform while none of them rated it as underperform, whereas none suggests the stock as a Sell. The stock has an overall rating of Overweight and investors could take advantage and scoop up stock of the company.
Looking further, we note that the PEG ratio for the ASLN stock currently stands at 0, and the current price level is 10.1% off its SMA20 and 22.11% from its 50-day simple moving average. The RSI (14) is pointing at 66.21 while the volatility over the past week is 8.14% and jumps to 8.38% over the past one month. The beta value is 0, while the average true range (ATR) is currently pointing at 0.15. The average price target for the stock over the next 12 months is $5.5, with the estimates having a low of $5 and a high of $6. These price ends are 143.9% and +192.68% off the current price level respectively, although investors could be excited at the prospect of a +168.29% if the ASLN share price touches on the median price of $5.5.
Let’s briefly compare ASLAN (ASLN) stock to its peers. We find that today’s price change of +7.33% and +29.75% over the past 12 months for ASLN betters that of Amgen Inc (AMGN), which has seen its stock price rise 0.3% in the latest trading session and is +15.8% over the last one year. Another of its peers Bristol-Myers Squibb Company (BMY) has climbed 1.36% today, and is +16.83% up over the past year, while Gilead Sciences Inc (GILD) is also up 7.33% yet its price remains in the green at 29.75% over the same period. Amgen has a P/E ratio of 19.26 compared to ASLAN’s 0 and Bristol-Myers 0. In contrast to these companies, both the S&P 500 Index and the Dow Jones Industrial are today at 0.01% and 0.39%, respectively, in early deals.
Coming back to ASLAN Pharmaceuticals Limited (NASDAQ:ASLN), we note that the average 3-month trading volume was 71.73 Million, while that of the preceding 10-day period stands at 42.59 Million. Current shares outstanding are 37.99 Million.
According to data from Thomson Reuters, insiders hold 0% of the company’s shares while institutions hold 8.68%. The data shows that short shares as of September 29, 2020, stood at 239.91 Million at a short ratio of 2.97. This represents a 0.63% Short interest in Shares outstanding on September 29, 2020. Shares short rose in September from the previous month at 142.21 Million. Investors should be excited about this stock as its upside potential is great, with today’s price pushing the stock +0.99% up in year-to-date price movement.